BDNF Gene Therapy Targets Obesity, Metabolic Disorders
Summary
The USPTO has published patent application US20260109997A1 for BDNF expression constructs and vectors intended to treat metabolic disorders including obesity. The application, filed on October 11, 2023 by five named inventors including Alexandria Forbes and Matthew During, claims the disclosed gene therapy is more effective than existing BDNF-based gene therapy constructs for metabolic indications.
“This disclosure provides BDNF expression constructs and vectors comprising such constructs for treating metabolic disorders, including, but not limited to, obesity.”
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 199 changes logged to date.
What changed
The USPTO published patent application US20260109997A1 for a BDNF (brain-derived neurotrophic factor) gene therapy targeting obesity and metabolic disorders. The application covers BDNF expression constructs and vectors, with the inventors claiming improved efficacy over existing BDNF-based gene therapy constructs.
For biotechnology and pharmaceutical companies engaged in metabolic disorder therapeutics or gene therapy development, this published application establishes a prior art date and signals an active development program in the BDNF gene therapy space. Companies with competing programs in obesity or metabolic gene therapy should review the disclosed claims for potential freedom-to-operate implications.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
BDNF GENE THERAPY
Application US20260109997A1 Kind: A1 Apr 23, 2026
Inventors
Alexandria Forbes, Josefa Sullivan, Ce Feng Liu, Matthew During, Natalia Fabela
Abstract
This disclosure provides BDNF expression constructs and vectors comprising such constructs for treating metabolic disorders, including, but not limited to, obesity. The disclosed BDNF gene therapy is more effective than existing BDNF-based gene therapy constructs.
CPC Classifications
C12N 15/86 A61K 38/185 A61K 48/005 A61P 3/04 C07K 14/475 C12N 2750/14143 C12N 2830/48 C12N 2830/50
Filing Date
2023-10-11
Application No.
19117728
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.